Scottsdale Health Partners’ success is derived from its physician engagement, care coordination and transformation, and meaningful IT usage, explained James Whitfill, MD, chief medical officer. The organization has also learned that direct contact with both patients and provider is critical to continuing that success.
Scottsdale Health Partners’ success is derived from its physician engagement, care coordination and transformation, and meaningful IT usage, explained James Whitfill, MD, chief medical officer. The organization has also learned that direct contact with both patients and provider is critical to continuing that success.
Transcript (modified)
Why do you think the Scottsdale Health Partners ACO has been successful at achieving shared savings?
So Scottsdale Health Partners, as an ACO and a clinically-integrated network, is a young organization, but we’ve had some early success that we’re very proud of. We think that that success probably comes from 3 main areas: physician engagement, the use of care coordination and care transformation, and the successful use of what I would call meaningful IT.
As a young ACO, what lessons has Scottsdale Health Partners learned?
So a couple of lessons that we’ve learned is that more direct contact either with our patients or our providers is critical for success. Models of care transformation where you just send out memos, or letters, or emails, or you just have web pages, we think is not enough. We have to still have that face-to-face interactions, and whether that’s with our patients who are at high risk and we’re trying to help them out and be healthier and use the healthcare system less, or with our physicians trying to learn the new way of value-based healthcare.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More